These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19064873)

  • 1. Disease-modifying therapy in multiple sclerosis: update and clinical implications.
    Goodin DS
    Neurology; 2008 Dec; 71(24 Suppl 3):S8-13. PubMed ID: 19064873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
    Durelli L
    J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-beta1b in multiple sclerosis.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2007 Mar; 7(3):227-39. PubMed ID: 17341170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon beta and multiple sclerosis: look at the evidence.
    Patti F; Reggio A
    Int J Clin Pract Suppl; 2002 Sep; (131):23-32. PubMed ID: 12564809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing treatment with interferon beta-1b (Betaferon/Betaseron) in the next decade--thinking beyond the standard dose.
    Cook SD
    J Neurol; 2003 Dec; 250 Suppl 4():IV15-20. PubMed ID: 14712397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
    Cristiano E
    Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment.
    Bayas A; Gold R
    J Neurol; 2003 Dec; 250 Suppl 4():IV3-8. PubMed ID: 14712395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early use of interferon beta patients with multiple sclerosis.
    Bosley EB; Capildeo R
    Int J Clin Pract Suppl; 2002 Sep; (131):17-22. PubMed ID: 12564808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
    Hurwitz BJ
    J Neurol Sci; 2008 Sep; 272(1-2):8-19. PubMed ID: 18620708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interferon beta treatment in multiple sclerosis].
    Ochi H
    Nihon Rinsho; 2003 Aug; 61(8):1367-73. PubMed ID: 12962025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey.
    Lundy J; Craig BM
    Clin Ther; 2006 Jan; 28(1):140-5. PubMed ID: 16490588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current landscape and unmet needs in multiple sclerosis.
    Markowitz CE
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S211-8. PubMed ID: 20873945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
    Thrower BW
    Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.